Article
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Dec 2008
Takano Toshimi, Fukui Tomoya, Ohe Yuichiro, Tsuta Koji, Yamamoto Seiichiro, Nokihara Hiroshi, Yamamoto Noboru, Sekine Ikuo, Kunitoh Hideo, Furuta Koh, Tamura Tomohide
Abstract excerpt
PURPOSE: This study evaluated whether the presence of epidermal growth factor receptor (EGFR) mutations is a predictive marker for survival benefit from gefitinib and/or a prognostic marker in patients with advanced lung adenocarcinoma. PATIENTS AND METHODS: Overall survival (OS) was compared bet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.